MannKind touts good news from Afrezza inhaled insulin trial

After being dogged by regulatory setbacks and demands for new trials, MannKind ($MNKD) says it has gathered clearly positive late-stage data on its inhaled insulin Afrezza from a pair of Phase III studies on Type 1 and Type 2 diabetes. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.